SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices approach all-time highs, fueled by speculation around potential Fed rate cuts and renewed interest in precious metals as a hedge against economic uncertainty. Community members are discussing technical breakouts, potential for a silver squeeze, and historical inflation-adjusted valuations, while some express concerns about market manipulation and potential pullbacks. The broader context involves increased industrial demand for silver and its role as a safe-haven asset amid global economic concerns.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy ($SWEAT) is gaining attention as users discuss the potential of earning crypto through physical activity. Community members highlight the project's long-term potential and token burn events, while others suggest it's currently undervalued. Discussions also revolve around the mechanics of earning $SWEAT and its availability on various exchanges.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne ($S) is garnering attention as investors debate its valuation and potential for growth within the cybersecurity sector. Community discussions revolve around upcoming earnings and whether it will trigger a breakout, with some speculating on a potential buyout given its perceived undervaluation compared to competitors. Despite positive developments, concerns linger around management and consistent profitability.

Global X Funds - Global X Funds Global X Robotics & Artificial Intelligence ETF

Global X Funds Global X Robotics & Artificial Intelligence ETF

$BOTZ is trending as investors weigh the potential of AI and robotics against concerns of a possible tech bubble and broader economic weakness. Discussions revolve around the ETF's key holdings, including NVDA, and its exposure to the US-China AI arms race, with community members analyzing its long-term growth prospects.

SPDR Series Trust - State Street SPDR S&P Oil & Gas Exploration & Production ETF

SPDR Oil & Gas Exploration & Production ETF

XOP is trending amid geopolitical tensions and shifting supply dynamics, with potential impacts from Iranian oil exports and OPEC+ production decisions driving market speculation. Community members are weighing the possibilities of further output cuts and debating the sector's undervaluation. Bullish investors are monitoring the ETF for potential breakouts, while others are cautious about demand in China and wider economic factors.

Morgan Stanley operates as a global financial services company. The firm provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. It operates through the following segments: Institutional Securities, Wealth Management, and Investment Management. The Institutional Services segment provides financial advisory, capital-raising services, and related financing services on behalf of institutional investors. The Wealth Management segment offers brokerage and investment advisory services covering various types of investments, including equities, options, futures, foreign currencies, precious metals, fixed-income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs. The Investment Management segment provides equity, fixed income, alternative investments, real estate, and merchant banking strategies. The company was founded by Harold Stanley and Henry S. Morgan in 1924 and is headquartered in New York, NY.

Morgan Stanley

Morgan Stanley ($MS) is trending amid discussions around bank regulations, potential M&A activity, and analysts weighing in on its financial outlook and strategic shifts. The community is focused on institutional ownership, potential earnings catalysts, and its position relative to competitors like Goldman Sachs ($GS). Recent news includes Morgan Stanley expanding crypto access and analysts adjusting price targets, driving both bullish and bearish sentiment.

SSgA Active Trust - Health Care Select Sector SPDR

Health Care Select Sector SPDR Fund

The Health Care Select Sector SPDR Fund ($XLV) is trending amid discussions of sector rotation and potential breakout opportunities, particularly as some analysts suggest a shift from technology into healthcare. Community members are actively trading call options on XLV, targeting higher price levels, while also weighing in on potential impacts from healthcare policy and individual companies within the sector. There is also discussion that a recent top may need to be retested.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending as the community discusses its long-term potential, interoperability and recent supply cap implementation.  Some investors view it as a solid project for cross-chain applications, while others are weighing its potential against emerging Layer 1 solutions focused on high-speed settlement and compliance.

Oxford Lane Capital Corp. is a closed-end management investment company, which engages in investing in debt and equity tranches of collateralized loan obligation vehicles. The company was founded on June 9, 2010 and is headquartered in Greenwich, CT.

Oxford Lane Capital Corp

OXLC is trending as investors weigh the impact of high dividend payouts and a recent reverse stock split. Community discussions revolve around the stock's potential for recovery, with some expressing concerns about long-term price erosion and others highlighting the potential for high yields if the dividend remains stable. Broader market factors, like interest rate decisions and sector-specific news, are also influencing investor sentiment.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KWEB is trending as traders discuss potential breakouts and a possible shift in global market dynamics favoring Chinese equities amid trade discussions. Bullish sentiment is fueled by signals of government support and potential for policy easing, while some analysts point to oversold conditions and attractive valuations compared to US tech. Community members are actively trading options and discussing key price levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Valneva (NASDAQ:VALN) Sees Strong Trading Volume - Here's What Happened

Valneva (NASDAQ:VALN) Sees Strong Trading Volume - What's Next...

Valneva's Lyme Vaccine VLA15 Shows Strong Phase 2 Booster Results With Favorable Safety

(RTTNews) - Valneva SE (VALN) announced positive final immunogenicity and safety data from its Phase 2 study, VLA15-221, evaluating the Lyme disease vaccine candidate VLA15. The study results...

Valneva (NASDAQ:VALN) Releases Earnings Results, Misses Estimates By $0.31 EPS

Valneva (NASDAQ:VALN - Get Free Report) announced its earnings results on Thursday. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.30) by...

Valneva (NASDAQ:VALN) Stock Price Up 3.4% - Time to Buy?

Valneva (NASDAQ:VALN) Stock Price Up 3.4% - Should You Buy...

Valneva (VALN) Projected to Post Earnings on Thursday

Valneva (NASDAQ:VALN) will be releasing its Q3 2025 earnings before the market opens on Thursday, November 20. (View Earnings Report at...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN...

Analysts on Monday expressed divergent opinions on vaccine company Valneva SE (VALN) after the firm said that the United States Food and Drug Administration (FDA) has suspended the license for its Chikungunya vaccine Ixchiq. Shares of Valneva tumbled over 19% on Monday.Jefferies analyst Maury Raycroft lowered the firm's price target on Valneva to $14 from $18 while keeping a ‘Buy’ rating on the shares following the news. The firm, which thinks there is some potential risk for ex-U.S. regulators to change their stance on Ixchiq licensure, added that Ixchiq is "not a major revenue driver" in the near term, according to TheFly.H.C. Wainwright analyst Brandon Folkes, meanwhile, reiterated a ‘Buy’ rating on Valneva. Despite the FDA's decision, Valneva has not revised its revenue guidance for 2025, the analyst noted. The stock selloff on Monday offers an attractive entry for investors who are constructive on a potential positive readout for VLA15, the company’s investigational Lyme disease vaccine, later this year, contends H.C. Wainwright. The firm views the selloff as overdone and keeps an $18 price target on Valneva, TheFly noted.On Stocktwits, retail sentiment around Valneva remained within ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_25_at_12_45_54_PM_png_bbe73f8bfa.webp" alt="VALN's Sentiment Meter and Message Volume as of 12:45 p.m. ET on Aug. 25, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>VALN's Sentiment Meter and Message Volume as of 12:45 p.m. ET on Aug. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user remains hopeful about the company getting acquired.<stembedurl>https://stocktwits.com/Papusa/message/626441643</stembedurl>Another, meanwhile, said that they are cutting their risk.<stembedurl>https://stocktwits.com/nroberts7/message/626439114</stembedurl>Valneva <a target="_blank" rel="noopener noreferrer nofollow" href="https://valneva.com/wp-content/uploads/2025/08/2025_08_25_FDA_IXCHIQ_Update_PR_EN_Final2.pdf">said</a> on Monday that the FDA suspended the license for Ixchiq in the U.S., citing four new reports of serious adverse events consistent with chikungunya-like illness. The suspension, it said, is effective immediately and requires the company to stop shipping and selling Ixchiq in the U.S.All four cases occurred outside the U.S., the company said. While three cases occurred in individuals aged 70 to 82 years, one case occurred in a 55-year-old individual. The company also said that an 82-year-old was hospitalized and discharged after two days.The firm said it believes all cases describe symptoms consistent with those reported during clinical trials, but added that it is continuing to investigate these cases in detail and will pursue further steps about the FDA’s decision if warranted.The company also said that it is evaluating the financial impact of the withdrawal of Ixchiq’s license in the U.S. However, it did not modify its revenue guidance. In the first half of 2025, Ixchiq contributed €7.5 million ($8.74 million) to the company’s €91 million total product sales.VALN stock is up by 116% this year and by about 18% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-exec-hints-at-possible-price-hike-on-model-y-in-us/chsssVVRdSR">Tesla Executive Hints At Possible Price Hike On Model Y In US: Retail Highlights Negative Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]comExchange Rate: €1= $1.16

An illustrative image of a person holding a medical syringe and a Covid-19 vaccine vial in front of the the Valneva logo displayed on a screen. On Wednesday, January 12, 2021, in Edmonton, Alberta, Canada. (Photo by Artur Widak/NurPhoto via Getty Images)

Valneva Stock Tumbles 19% After FDA Suspension Of Ixchiq License In US, Wall Street Divided On The Impact

While Jefferies lowered its price target on Valneva, H.C. Wainwright kept its $18 price target unchanged. 

Equity

While Jefferies lowered its price target on Valneva, H.C. Wainwright kept its $18 price target unchanged. 



Valneva (VALN) Soars 17.4%: Is Further Upside Left in the Stock?

Valneva (VALN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Valneva SE (VALN, $7.68) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This indicator may be signaling that VALN's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.

Valneva SE - ADR

$AMZN

$MSFT

$GOOGL

$ORCL

Which cloud infrastructure stock offers the best long-term opportunity right now?

Current Price	$9.30
Prev Close	$9.54
Open	$9.41
Dividend Yield	0.00%
50-Day Moving Average	$9.77
Beta	0.95
Avg. Volume	49,472.00
PE Ratio	-6.82

52-Week High	$12.25
52-Week Low	$3.62
Market Capitalization	$803.75M
EPS (Annual)	-$0.1818
Price to Book	4.54
Revenue Per Employee	$257,267.93
Enterprise Value/EBITDA	N/A

VALN
Valneva SE - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VALN News

VALNValneva SE - ADR